November 10, 2020 07:24 AM ESTUpdated 10:46 AM
R&D

Mer­ck pulls the plug on a study eval­u­at­ing block­buster Keytru­da with Yer­voy for NSCLC

Nicole DeFeudis

Editor

About a month ago, up­on tout­ing new on­col­o­gy da­ta, Mer­ck reaf­firmed its com­mit­ment to ex­plor­ing new Keytru­da com­bi­na­tions for lung can­cer pa­tients. The Big …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

No­vo Nordisk part­ners with Broad In­sti­tute spin­out Pho­tys af­ter the star­tup's lay­offs

Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force in lat­est job cuts

Ex­clu­sive: In­sitro makes head­way on the hard­er road, dis­cov­er­ing new ALS drug tar­get

SiteOne Ther­a­peu­tics, a pain biotech that's part­nered with Ver­tex, nabs $100M

Tessera gets up to $50M from the Gates Foun­da­tion; Tvar­di’s re­verse merg­er

A service from the Financial Times